On Friday, TransCode Therapeutics Inc (NASDAQ: RNAZ) opened higher 45.45% from the last session, before settling in for the closing price of $0.77. Price fluctuations for RNAZ have ranged from $0.64 to $66.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 95.41% at the time writing. With a float of $0.63 million, this company’s outstanding shares have now reached $0.70 million.
Let’s determine the extent of company efficiency that accounts for 10 employees. In terms of profitability, gross margin is 43.62%, operating margin of -1947.19%, and the pretax margin is -1981.89%.
TransCode Therapeutics Inc (RNAZ) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of TransCode Therapeutics Inc is 5.08%, while institutional ownership is 26.18%.
TransCode Therapeutics Inc (RNAZ) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 95.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 78.85% during the next five years compared to -28.81% drop over the previous five years of trading.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Trading Performance Indicators
Check out the current performance indicators for TransCode Therapeutics Inc (RNAZ). In the past quarter, the stock posted a quick ratio of 1.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -265.83, a number that is poised to hit -105.93 in the next quarter and is forecasted to reach -144.21 in one year’s time.
Technical Analysis of TransCode Therapeutics Inc (RNAZ)
Looking closely at TransCode Therapeutics Inc (NASDAQ: RNAZ), its last 5-days average volume was 44.92 million, which is a jump from its year-to-date volume of 6.84 million. As of the previous 9 days, the stock’s Stochastic %D was 23.30%. Additionally, its Average True Range was 0.79.
During the past 100 days, TransCode Therapeutics Inc’s (RNAZ) raw stochastic average was set at 2.23%, which indicates a significant decrease from 30.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 235.29% in the past 14 days, which was higher than the 222.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.1362, while its 200-day Moving Average is $13.5672. However, in the short run, TransCode Therapeutics Inc’s stock first resistance to watch stands at $1.5723. Second resistance stands at $2.0247. The third major resistance level sits at $2.3793. If the price goes on to break the first support level at $0.7653, it is likely to go to the next support level at $0.4107.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Key Stats
There are currently 696K shares outstanding in the company with a market cap of 0.78 million. Presently, the company’s annual sales total 0 K according to its annual income of -18,550 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -2,320 K.
